ArticleAnnals of intensive care2019
Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial.
Article in Annals of intensive care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock.Critical care (London, England) · 2025Trial
- Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.Critical care (London, England) · 2023Trial
- Role of Angiotensin II as a Vasoactive Agent to Treat Distributive Shock With a Focus on Preliminary Data in Pediatric-Aged Patients.Paediatric anaesthesia · 2026Review
- Hydroxocobalamin for vasoplegia in cardiac surgery: a retrospective cohort analysis.British journal of anaesthesia · 2025Article
- Targeting high circulating dipeptidyl peptidase 3 in circulatory failure.Critical care (London, England) · 2025Review
- Angiotensin II, conventional vasopressor therapy, and mortality in shock: a large, multicenter, propensity score-weighted analysis.Annals of intensive care · 2025Article
- Early multimodal vasopressor strategy in septic shock (TRICYCLE)-Study protocol for a randomized controlled clinical trial.PloS one · 2025Article
- The renin-angiotensin-aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II.Critical care (London, England) · 2024Review
- Impaired angiotensin II signaling in septic shock.Annals of intensive care · 2024Review
- Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury.Intensive care medicine experimental · 2024Article
- Circulating Dipeptidyl Peptidase 3 Modulates Systemic and Renal Hemodynamics Through Cleavage of Angiotensin Peptides.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials.Critical care (London, England) · 2024Review
- Angiotensin II - A Brief Review and Role in Severe SARS-COV-2 Sepsis.Journal of cardiothoracic and vascular anesthesia · 2022Review
- Alternatives to norepinephrine in septic shock: Which agents and when?Journal of intensive medicine · 2022Review
- The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia.Cardiovascular drugs and therapy · 2022Review
- Vasopressor Choice and Timing in Vasodilatory Shock.Critical care (London, England) · 2022Review
- A Multicenter Observational Cohort Study of Angiotensin II in Shock.Journal of intensive care medicine · 2022Observational
- Review
- Observational
- In Response.Anesthesia and analgesia · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly clinical data showed that some patients with vasodilatory shock are responsive to low doses of angiotensin II. The objective of this analysis was to compare clinical outcomes in patients requiring ≤ 5 ng kg
resultsThe subgroup of patients whose angiotensin II dose was down-titrated from 20 ng kg
conclusionsThis prespecified analysis showed that down-titration to ≤ 5 ng kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.